Imagerie Beta-CIT SPECT des transporteurs de dopamine et de sérotonine chez les patients neuropsychiatriques
Cette étude vise à observer et à comprendre les niveaux de transporteurs de dopamine et de sérotonine chez les patients neuropsychiatriques en utilisant l'imagerie Beta-CIT SPECT.
Collecte de données
Troubles anxieux+16
+ Maladies des ganglions de la base
+ Maladies du cerveau
Résumé
Date de début de l'étude : 1 mai 1998
Date à laquelle le premier participant a commencé l'étude.Abnormalities in the re-uptake of dopamine and serotonin have been described in various neuropsychiatric disorders and substance abuse. [I-123] Beta-CIT is a recently developed radioligand for SPECT imaging of dopamine and serotonin transporters. [I-123]Beta-CIT SPECT has been used at the SPECT-Lab of the Clinical Brain Disorders Branch in over fifty subjects without adverse events. Due to the trace concentrations used, a pharmacological effect of Beta-CIT is unlikely and has not been observed. The purpose of this study is to use Beta-CIT and SPECT to study the expression of dopamine and serotonin transporters in vivo in normal controls and various patient populations to address hypothesized abnormalities of the transporters in different disorders and to understand the effects of genetic variations in the genes of these transporters on their in vivo expression.
Protocole
Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.112 participants à inclure
Nombre total de participants que l'essai clinique vise à recruter.Éligibilité
Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.Tout sexe
Le sexe biologique des participants éligibles à s'inscrire.Volontaires sains autorisés
Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.Conditions
Pathologie
Critères
INCLUSION CRITERIA: No Axis I or Axis II diagnoses. EXCLUSION CRITERIA FOR ALL SUBJECTS: If the pregnancy test is positive or if the woman has reason to believe she might be pregnant, she will be excluded from this study. Women who are breastfeeding will be excluded from this study to avoid unwarranted risk to their children. Subjects with a prior reaction to iodine, iodine compounds, or shellfish will be excluded from this study. Subjects with a history of thyroid disease or dysfunction will be excluded from this study. Subjects with a history of recent substance abuse will be excluded from this study. Subjects with metal objects in their bodies as specified in our MRI protocol (91-M-0124) will be excluded from this study. If a structural abnormality of the brain is detected on MRI, subjects will be excluded from the study. EXCLUSION CRITERIA FOR NORMAL CONTROLS: Subjects with an Axis I or Axis II disorder will be excluded. Subjects with concomitant medical or neurological disorders which require ongoing medication, or which may affect the central nervous system will be excluded.
Centres d'étude
Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.Cette étude comporte 1 site
National Institute of Mental Health (NIMH)
Bethesda, United StatesOuvrir National Institute of Mental Health (NIMH) dans Google Maps